



# Koko Xsu Venture Company Fund 1, LP

## Unaudited financial statements

For the period from January 1, 2025 to March 31, 2025

# Koko Xsu Venture Company Fund 1, LP

## Statement of assets, liabilities, and partners' capital

March 31, 2025

---

### Assets

---

Investments, at fair value (cost \$4,354,488)	\$	4,571,293
Cash		1,176,965
Capital contributions receivable		13,015
<b>Total assets</b>	<b>\$</b>	<b>5,761,273</b>

---

---

### Liabilities and partners' capital

#### Liabilities

---

Due to related parties	\$	(19,333)
<i>Tax</i>		1,750
<b>Accrued expenses</b>		<b>1,750</b>
Accounts payable		309,991
Capital contributions received in advance		97,719
Management fee payable		(39,331)
<b>Total liabilities</b>		<b>350,796</b>

---

#### Partners' capital

---

<b>Total partners' capital</b>		<b>5,410,477</b>
<b>Total liabilities and partners' capital</b>	<b>\$</b>	<b>5,761,273</b>

---

---

# Koko Xsu Venture Company Fund 1, LP

## Schedule of investments

March 31, 2025

Investments, at fair value	Invt. date	Shares	Cost	Fair value	Unrealized gain (loss)	Cost/share	Fair value/share
<b>Adagy Robotics, Inc.</b>							
SAFE	05/28/2024	— \$	5,000 \$	5,000 \$	— \$	— \$	—
<b>Antares Systems Inc.</b>							
			355,000	355,000	—	—	—
SAFE	07/01/2024	—	5,000	5,000	—	—	—
SAFE	08/13/2024	—	350,000	350,000	—	—	—
<b>Aspect Health Global INC</b>							
SAFE	02/10/2025	—	750,000	750,000	—	—	—
<b>Elide Interfaces, Inc.</b>							
SAFE	11/28/2023	—	5,000	5,000	—	—	—
<b>Etched.ai, Inc.</b>							
SAFE	04/10/2023	—	5,000	5,000	—	—	—
<b>General Biological Corporation</b>							
SAFE	04/02/2024	—	5,000	5,000	—	—	—
<b>Lemi, Inc.</b>							
			304,991	359,107	54,116	—	—
Series A-1 Preferred	12/24/2024	30,346	299,991	299,991	—	9.89	9.89
Series A-3 Preferred	12/24/2024	5,980	5,000	59,116	54,116	0.84	9.89
<b>Mach Industries Inc.</b>							
			19,997	61,811	41,814	—	—
Series A-1 Preferred	09/13/2023	1,085	14,997	14,997	—	13.82	13.82
Series A-3 Preferred	09/13/2023	3,387	5,000	46,814	41,814	1.48	13.82

# Koko Xsu Venture Company Fund 1, LP

## Schedule of investments (continued)

March 31, 2025

Investments, at fair value	Invt. date	Shares	Cost	Fair value	Unrealized gain (loss)	Cost/share	Fair value/share
<b>MindCo Labs, Inc.</b>		\$	<b>450,000</b>	\$	<b>450,000</b>	\$	
SAFE	04/29/2024	—	50,000	50,000	—	—	—
SAFE	08/16/2024	—	400,000	400,000	—	—	—
<b>Oglío Incorporated</b>							
SAFE	04/24/2024	—	10,000	10,000	—	—	—
<b>Oligo Incorporated</b>			<b>750,000</b>	<b>750,000</b>	—	—	—
SAFE	12/19/2024	—	200,000	200,000	—	—	—
SAFE	02/06/2025	—	550,000	550,000	—	—	—
<b>Opal Camera, Inc.</b>							
AngelList	08/15/2024	—	5,000	5,000	—	—	—
<b>Orbit Technologies, Inc.</b>			<b>855,000</b>	<b>975,875</b>	<b>120,875</b>	—	—
Series Seed Preferred	12/23/2024	266,514	700,000	764,648	64,648	2.63	2.87
Series Seed-1 Preferred	12/23/2024	10,168	5,000	29,173	24,173	0.49	2.87
Series Seed-2 Preferred	12/23/2024	63,454	150,000	182,054	32,054	2.36	2.87
<b>Redwood Technology Holdings, Inc.</b>							
SAFE	11/19/2024	—	99,500	99,500	—	—	—
<b>Scale Medicine, Inc.</b>							
SAFE	07/04/2024	—	10,000	10,000	—	—	—
<b>Singularity Space, Inc.</b>							
SAFE	05/20/2024	—	5,000	5,000	—	—	—

# Koko Xsu Venture Company Fund 1, LP

## Schedule of investments (continued)

March 31, 2025

Investments, at fair value	Invt. date	Shares	Cost	Fair value	Unrealized gain (loss)	Cost/share	Fair value/share
<b>Tilde Research Inc.</b>							
SAFE	08/13/2024	— \$	100,000 \$	100,000 \$	— \$	— \$	—
<b>Vigil Labs, Inc.</b>							
SAFE	02/11/2025	—	320,000	320,000	—	—	—
<b>Total - company investments</b>		<b>\$</b>	<b>4,054,488</b>	<b>\$</b>	<b>4,271,293</b>	<b>\$</b>	<b>216,805</b>
<b>FBV 1 A Series of SLRTE I LLC (Seed Labs LLC)</b>							
Membership Interest	02/07/2025	—	150,000	150,000	—	—	—
<b>Haize Labs: SPV Jun 2024, a Series of CGF2021 LLC</b>							
Membership Interest	08/14/2024	—	150,000	150,000	—	—	—
<b>Total - fund investments</b>		<b>\$</b>	<b>300,000</b>	<b>\$</b>	<b>300,000</b>	<b>\$</b>	<b>—</b>
<b>Total</b>		<b>\$</b>	<b>4,354,488</b>	<b>\$</b>	<b>4,571,293</b>	<b>\$</b>	<b>216,805</b>

The following table summarizes the investments by asset type:

Asset type	Cost	Fair value	Unrealized gain (loss)
<b>SAFEs</b>	\$ 2,869,500	\$ 2,869,500	\$ —
<b>Preferred stock</b>	1,179,988	1,396,793	216,805
<b>Fund investment</b>	300,000	300,000	—
<b>Other</b>	5,000	5,000	—
<b>Total</b>	<b>\$ 4,354,488</b>	<b>\$ 4,571,293</b>	<b>\$ 216,805</b>

# Koko Xsu Venture Company Fund 1, LP

## Statement of operations

For the period from January 1, 2025 to March 31, 2025

---

### Expenses

Management fees	\$	49,725
Tax preparation fees		8,750
Legal fees		8,488
Fund administration fees		5,000
<b>Total professional fees</b>		<b>22,238</b>
Deal fees		1,770
<b>Total expenses</b>		<b>73,733</b>
<b>Net investment loss</b>		<b>(73,733)</b>
<hr/>		
<b>Net decrease in partners' capital from operations</b>	\$	<b>(73,733)</b>

---

# Koko Xsu Venture Company Fund 1, LP

## Statement of changes in partners' capital

For the period from January 1, 2025 to March 31, 2025

	General Partner		Limited Partners		Total
Partners' capital, beginning of period	\$	64,752	\$	5,419,459	\$ 5,484,211
Management fees		—		(49,725)	(49,725)
Net operating income (loss)		(2,237)		(21,772)	(24,009)
Carried interest accrued		(10,885)		10,885	—
Partners' capital, end of period	\$	51,630	\$	5,358,847	\$ 5,410,477

# Koko Xsu Venture Company Fund 1, LP

## Statement of cash flows

For the period from January 1, 2025 to March 31, 2025

---

### Cash flows from operating activities

---

Net decrease in partners' capital from operations	\$	(73,733)
Adjustments to reconcile net decrease in partners' capital from operations to net cash used in operating activities:		
Purchase of investments		(1,770,000)
Changes in operating assets and liabilities:		
Increase in accrued expenses		1,750
Decrease in management fee payable		(49,725)
Decrease in due to related parties		(56,486)
<b>Net cash used in operating activities</b>		<b>(1,948,194)</b>

---

### Cash flows from financing activities

---

Capital contributions, net of change in capital contributions receivable		1,287
<b>Net cash provided by financing activities</b>		<b>1,287</b>

---

<b>Net decrease in cash</b>		<b>(1,946,907)</b>
<b>Cash, beginning of period</b>		<b>3,123,872</b>
<b>Cash, end of period</b>	<b>\$</b>	<b>1,176,965</b>

---

---